{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:30:41Z","timestamp":1786980641766,"version":"build-2736575974"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"13-14","license":[{"start":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T00:00:00Z","timestamp":1401926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Med Wochenschr"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s10354-014-0285-x","type":"journal-article","created":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T17:50:12Z","timestamp":1401904212000},"page":"263-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Pyoderma gangrenosum: pathogenetic oriented treatment approaches","Pyoderma gangraenosum \u2013 pathogenetisch orientierte Behandlungsoptionen"],"prefix":"10.1007","volume":"164","author":[{"given":"Uwe","family":"Wollina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Tchernev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,6,5]]},"reference":[{"key":"285_CR1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1001\/archderm.1930.01440160053009","volume":"22","author":"LA Brunsting","year":"1930","unstructured":"Brunsting LA, Goeckerman WH, O\u2019Leary PA. Pyoderma [ecthyma] gangrenosum: Clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph. 1930;22:655\u201380.","journal-title":"Arch Dermatol Syph"},{"key":"285_CR2","first-page":"56","volume":"7","author":"G Tchernev","year":"2005","unstructured":"Tchernev G, Trebing D, G\u00f6ring H-D, Steinhoff M, Zouboulis CC, Orfanos C. Pyoderma gangrenosum in Crohn\u2019s disease\u2014the role of immunologic parameters and histological data in diagnosis and differential diagnosis. Bulg J Hepatogastroenterol. 2005;7:56\u201360.","journal-title":"Bulg J Hepatogastroenterol"},{"key":"285_CR3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00128071-200203030-00002","volume":"3","author":"U Wollina","year":"2002","unstructured":"Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol. 2002;3:149\u201358.","journal-title":"Am J Clin Dermatol"},{"key":"285_CR4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.smim.2013.10.008","volume":"25","author":"CA Dinarello","year":"2013","unstructured":"Dinarello CA, van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. 2013;25:469\u201384. doi: 10.1016\/j.smim.2013.10.008.","journal-title":"Semin Immunol"},{"key":"285_CR5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.annder.2012.03.012","volume":"139","author":"D Lipsker","year":"2012","unstructured":"Lipsker D, Lenormand C. Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Ann Dermatol Venereol. 2012;139:459\u201367.","journal-title":"Ann Dermatol Venereol"},{"key":"285_CR6","first-page":"447","volume":"11","author":"L Kowalzick","year":"2013","unstructured":"Kowalzick L, Bertolini J, Baumann C, Walther B, Truhm B, Eickenscheidt L. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis. J Dtsch Dermatol Ges. 2013;11:447\u20139.","journal-title":"J Dtsch Dermatol Ges"},{"key":"285_CR7","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1684\/ejd.2012.1849","volume":"22","author":"N Kikuchi","year":"2012","unstructured":"Kikuchi N, Hiraiwa T, Ohashi T, Hanami Y, Satoh M, Takenoshita H, et al. Pyoderma gangrenosum possibly triggered by adalimumab. Eur J Dermatol. 2012;22:804\u20135.","journal-title":"Eur J Dermatol"},{"key":"285_CR8","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/archderm.144.6.817","volume":"144","author":"M Stichenwirth","year":"2008","unstructured":"Stichenwirth M, Riedl E, Pehamberger H, Tappeiner G. Pyoderma gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? Arch Dermatol. 2008;144:817\u20138.","journal-title":"Arch Dermatol"},{"key":"285_CR9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/09546631003797106","volume":"22","author":"MM Kleinpenning","year":"2011","unstructured":"Kleinpenning MM, Langewouters AM, Van De Kerkhof PC, Greebe RJ. Severe pyoderma gangrenosum unresponsive to etanercept and adalimumab. J Dermatolog Treat. 2011;22:261\u20135.","journal-title":"J Dermatolog Treat"},{"key":"285_CR10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1750-1172-2-19","volume":"2","author":"U Wollina","year":"2007","unstructured":"Wollina U. Pyoderma gangrenosum\u2014a review. Orphanet J Rare Dis. 2007;2:19.","journal-title":"Orphanet J Rare Dis"},{"key":"285_CR11","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(96)90428-4","volume":"34","author":"FC Powell","year":"1996","unstructured":"Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol. 1996;34:395\u2013409.","journal-title":"J Am Acad Dermatol"},{"key":"285_CR12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MD.0b013e318187cc9c","volume":"87","author":"D Farhi","year":"2008","unstructured":"Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2,402 patients. Medicine (Baltimore). 2008;87:281\u201393.","journal-title":"Medicine (Baltimore)"},{"key":"285_CR13","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/ajg.2010.343","volume":"106","author":"SR Vavricka","year":"2011","unstructured":"Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol. 2011;106:110\u20139.","journal-title":"Am J Gastroenterol"},{"key":"285_CR14","doi-asserted-by":"crossref","unstructured":"Langan SM, Groves RW, Card TR, Gulliford MC. Incidence, mortality, and disease associations of pyoderma gangrenosum in the United Kingdom: a retrospective cohort study. J Invest Dermatol. 2012;132:2166\u201370.","DOI":"10.1038\/jid.2012.130"},{"key":"285_CR15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1525-1470.1994.tb00065.x","volume":"11","author":"JA Graham","year":"1994","unstructured":"Graham JA, Hansen KK, Rabinowitz LG, Esterly NB. Pyoderma gangrenosum in infants and children. Pediatr Dermatol. 1994;11:10\u20137.","journal-title":"Pediatr Dermatol"},{"key":"285_CR16","first-page":"51","volume":"4","author":"JP Callen","year":"1989","unstructured":"Callen JP. Pyoderma gangrenosum and related disorders. Adv Dermatol. 1989;4:51\u201369.","journal-title":"Adv Dermatol"},{"key":"285_CR17","first-page":"1140","volume-title":"Dermatology in general medicine","author":"K Wolff","year":"1999","unstructured":"Wolff K, Stingl G. Pyoderma gangrenosum. In: Freedberg IM, Eisen AZ, Wolff K, Austen FK, Goldsmith LA, Katz SI, et al., editors. Dermatology in general medicine. New York: McGraw Hill; 1999. pp.\u00a01140\u20138."},{"key":"285_CR18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2133.1983.tb03966.x","volume":"108","author":"FC Powell","year":"1983","unstructured":"Powell FC, Schroeter AL, Perry HO, Su WP. Direct immunofluorescence in pyoderma gangrenosum. Br J Dermatol. 1983;108:287\u201393.","journal-title":"Br J Dermatol"},{"key":"285_CR19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1523-1747.1998.00255.x","volume":"111","author":"S Shaya","year":"1998","unstructured":"Shaya S, Kindzelskii AL, Minor J, Moore EC, Todd RF 3rd, Petty HR. Aberrant integrin [CR4; \u03b1x\u03b22; CD11c\/CD18] oscillation on neutrophils in a mild form of pyoderma gangrenosum. J Invest Dermatol. 1998;111:154\u20138.","journal-title":"J Invest Dermatol"},{"key":"285_CR20","doi-asserted-by":"crossref","unstructured":"Adachi Y, Kindzelskii AL, Cookingham G, Shaya S, Moore EC, Todd RF 3rd. Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol. 1998;111:259\u201368.","DOI":"10.1046\/j.1523-1747.1998.00311.x"},{"key":"285_CR21","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1067\/mjd.2003.305","volume":"48","author":"HH Sams","year":"2003","unstructured":"Sams HH, Mitchell MM, Stratton CW, King LE Jr. Culture and immunohistochemical evidence of chlamydia infection in ulcerative pyoderma gangrenosum. J Am Acad Dermatol. 2003;48:966\u20139.","journal-title":"J Am Acad Dermatol"},{"key":"285_CR22","first-page":"232","volume":"9","author":"M Braun-Falco","year":"2011","unstructured":"Braun-Falco M, Ruzicka T. Skin manifestations in autoinflammatory syndromes. J Dtsch Dermatol Ges. 2011;9:232\u201346.","journal-title":"J Dtsch Dermatol Ges"},{"key":"285_CR23","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s00108-009-2302-5","volume":"50","author":"P Lamprecht","year":"2009","unstructured":"Lamprecht P, Gross WL. Autoinflammatory syndromes. Internist (Berl). 2009;50:676\u201384.","journal-title":"Internist (Berl)"},{"key":"285_CR24","first-page":"w13590","volume":"142","author":"E Contassot","year":"2012","unstructured":"Contassot E, Beer HD, French LE. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly. 2012;142:w13590.","journal-title":"Swiss Med Wkly"},{"key":"285_CR25","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2013.03.016","volume":"147","author":"deJA Almeida","year":"2013","unstructured":"Almeida de jA, Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin Immunol. 2013;147:155\u201374.","journal-title":"Clin Immunol"},{"key":"285_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/BOR.0b013e328341152f","volume":"23","author":"U Wollina","year":"2011","unstructured":"Wollina U, Haroske G. Pyoderma gangraenosum. Curr Opin Rheumatol. 2011;23:50\u20136.","journal-title":"Curr Opin Rheumatol"},{"key":"285_CR27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1365-2230.2011.04137.x","volume":"36","author":"AB Nesterovitch","year":"2011","unstructured":"Nesterovitch AB, Hoffman MD, Simon M, Petukhov PA, Tharp MD, Glant TT. Mutations in the PSTPIP1 gene and aberrant splicing variants in patients with pyoderma gangrenosum. Clin Exp Dermatol. 2011;36:889\u201395.","journal-title":"Clin Exp Dermatol"},{"key":"285_CR28","doi-asserted-by":"crossref","first-page":"13501","DOI":"10.1073\/pnas.2135380100","volume":"100","author":"NG Shoham","year":"2003","unstructured":"Shoham NG, Centola M, Mansfield E, Hull KM, Wood G, Wise CA, et al. Pyrin binds the PSTPIP1\/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathway. Proc Natl Acad Sci U S A. 2003;100:13501\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"285_CR29","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1038\/ni.2749","volume":"14","author":"H Hara","year":"2013","unstructured":"Hara H, Tsuchiya K, Kawamura I, Fang R, Hernandez-Cuellar E, Shen Y, et al. Phosphorylation of the adaptor ASC acts as a molecular switch that controls the formation of speck-like aggregates and inflammasome activity. Nat Immunol. 2013;14:1247\u201355.","journal-title":"Nat Immunol"},{"key":"285_CR30","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s00018-013-1524-9","volume":"71","author":"A Salminen","year":"2014","unstructured":"Salminen A, Kauppinen A, Hiltunen M, Kaarniranta K. Epigenetic regulation of ASC\/TMS1 expression: potential role in apoptosis and inflammasome function. Cell Mol Life Sci. 2014;71:1855\u201364.","journal-title":"Cell Mol Life Sci"},{"key":"285_CR31","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1055\/s-0029-1242011","volume":"134","author":"U M\u00fcller-Ladner","year":"2009","unstructured":"M\u00fcller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, et al. \u201cTRECID\u201d, TNFalpha related chronic inflammatory diseases\u2014a new multiple diseases bridging concept. Dtsch Med Wochenschr. 2009;134:2132\u20136.","journal-title":"Dtsch Med Wochenschr"},{"key":"285_CR32","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000354703","volume":"31","author":"K Fellermann","year":"2013","unstructured":"Fellermann K. Adverse events of tumor necrosis factor inhibitors. Dig Dis. 2013;31:374\u20138.","journal-title":"Dig Dis"},{"key":"285_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00128071-200809010-00001","volume":"9","author":"U Wollina","year":"2008","unstructured":"Wollina U, Hansel G, Koch A, Sch\u00f6nlebe J, K\u00f6stler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol. 2008;9:1\u201314.","journal-title":"Am J Clin Dermatol"},{"key":"285_CR34","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1529-8019.2012.01488.x","volume":"25","author":"CR Schadt","year":"2012","unstructured":"Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther. 2012;25:158\u201372.","journal-title":"Dermatol Ther"},{"key":"285_CR35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/1750-1172-8-136","volume":"8","author":"PH Al Ghazal","year":"2013","unstructured":"Al Ghazal PH, Herberger K, Schaller J, Str\u00f6lin A, Hoff NP, Goerge T, et al. Associated factors and comorbidities in patients with pyoderma gangrenosum in Germany: a retrospective multicentric analysis in 259 patients. Orphanet J Rare Dis. 2013;8:136.","journal-title":"Orphanet J Rare Dis"},{"key":"285_CR36","first-page":"173","volume":"55","author":"F Powell","year":"1985","unstructured":"Powell F, Schroeter A, Su W, Perry H. Pyoderma gangrenosum: a review of 86 patients. Q J Med. 1985;55:173\u201386.","journal-title":"Q J Med"},{"key":"285_CR37","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1159\/000284583","volume":"220","author":"CS Seitz","year":"2010","unstructured":"Seitz CS, Berens N, Br\u00f6cker EB, Trautmann A. Leg ulceration in rheumatoid arthritis\u2014an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. Dermatology. 2010;220:268\u201373.","journal-title":"Dermatology"},{"key":"285_CR38","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/1346-8138.12359","volume":"40","author":"M Hasegawa","year":"2013","unstructured":"Hasegawa M, Nagai Y, Sogabe Y, Hattori T, Inoue C, Okada E, et al. Clinical analysis of leg ulcers and gangrene in rheumatoid arthritis. J Dermatol. 2013;40:949\u201354.","journal-title":"J Dermatol"},{"key":"285_CR39","doi-asserted-by":"crossref","unstructured":"Chia HY, Tang MB. Chronic leg ulcers in adult patients with rheumatological diseases\u2014a 7-year retrospective review. Int Wound J. 2012;doi: 10.1111\/iwj.12012. [Epub ahead of print]","DOI":"10.1111\/iwj.12012"},{"key":"285_CR40","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.clindermatol.2005.01.017","volume":"23","author":"U Wollina","year":"2005","unstructured":"Wollina U, Hein G. Lupus erythematosus: uncommon presentations. Clin Dermatol. 2005;23:470\u20139.","journal-title":"Clin Dermatol"},{"key":"285_CR41","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10067-006-0306-2","volume":"26","author":"V Reddy","year":"2007","unstructured":"Reddy V, Dziadzio M, Hamdulay S, Boyce S, Prasad N, Keat A. Lupus and leg ulcers\u2013a diagnostic quandary. Clin Rheumatol. 2007;26:1173\u20135.","journal-title":"Clin Rheumatol"},{"key":"285_CR42","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3899\/jrheum.110479","volume":"39","author":"J Feld","year":"2012","unstructured":"Feld J, Bergman R, Weltfriend S, Zisman D. Pyoderma gangrenosum in a patient with systemic sclerosis. J Rheumatol. 2012;39:197.","journal-title":"J Rheumatol"},{"key":"285_CR43","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2133.2007.07964.x","volume":"157","author":"M Fujikura","year":"2007","unstructured":"Fujikura M, Ohtsuka T, Oyamada Y. Systemic sclerosis in association with peristomal pyoderma gangrenosum. Br J Dermatol. 2007;157:618\u20139.","journal-title":"Br J Dermatol"},{"key":"285_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2230.1996.tb00042.x","volume":"21","author":"M Shah","year":"1996","unstructured":"Shah M, Lewis FM, Harrington CI. Scrotal pyoderma gangrenosum associated with dermatomyositis. Clin Exp Dermatol. 1996;21:151\u20133.","journal-title":"Clin Exp Dermatol"},{"key":"285_CR45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/978-94-007-4546-9_39","volume":"755","author":"K Zycinska","year":"2013","unstructured":"Zycinska K, Wardyn K, Zielonka TM, Nitsch-Osuch A, Smolarczyk R. Cutaneous changes: an initial manifestation of pulmonary Wegener\u2019s granulomatosis. Adv Exp Med Biol. 2013;755:307\u201310.","journal-title":"Adv Exp Med Biol"},{"key":"285_CR46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/MPG.0b013e31819a62f5","volume":"50","author":"U Halac","year":"2010","unstructured":"Halac U, Al Dhaybi R, Powell J, Bouron-Dal Soglio D, Alvarez F. Unusual association between autoimmune hepatitis and severe pyoderma gangrenosum. J Pediatr Gastroenterol Nutr. 2010;50:219\u201321.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"285_CR47","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10067-008-1066-y","volume":"28","author":"PK Chandrasekhara","year":"2009","unstructured":"Chandrasekhara PK, Jayachandran NV, Thomas J, Agrawal S, Narsimulu G. Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone. Clin Rheumatol. 2009;28:489\u201390.","journal-title":"Clin Rheumatol"},{"key":"285_CR48","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1684\/ejd.2009.0685","volume":"19","author":"A Ravic-Nikolic","year":"2009","unstructured":"Ravic-Nikolic A, Milicic V, Ristic G, Jovovic-Dagovic B. Pyoderma gangrenosum associated with Sj\u00f6gren syndrome. Eur J Dermatol. 2009;19:392\u20133.","journal-title":"Eur J Dermatol"},{"key":"285_CR49","doi-asserted-by":"crossref","unstructured":"Richetta AG, D\u2019Epiro S, Mattozzi C, Giancristoforo S, Calvieri S. Folgoration as an example of pathergy in a patient affected by pyoderma gangrenosum and Takayasu\u2019s arteritis. Dermatol Res Pract. 2009;2009:393452.","DOI":"10.1155\/2009\/393452"},{"key":"285_CR50","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.revmed.2007.03.010","volume":"28","author":"A Dejardin Botelho","year":"2007","unstructured":"Dejardin Botelho A, Delesalle F, Delaporte E, Wallaert B. Pyoderma gangrenosum and Churg-Strauss syndrome. Rev Med Interne. 2007;28:564\u20135.","journal-title":"Rev Med Interne"},{"key":"285_CR51","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/j.1525-1470.2008.00784.x","volume":"25","author":"AJ Mehta","year":"2008","unstructured":"Mehta AJ, Charman CR. Pyoderma gangrenosum in association with autoimmune neutropenia of infancy. Pediatr Dermatol. 2008;25:620\u20132.","journal-title":"Pediatr Dermatol"},{"key":"285_CR52","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1046\/j.1365-2133.2000.03606.x","volume":"143","author":"EA Coors","year":"2000","unstructured":"Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol. 2000;143:154\u20136.","journal-title":"Br J Dermatol"},{"key":"285_CR53","first-page":"57","volume":"14","author":"M Necas","year":"2005","unstructured":"Necas M, Semr\u00e1dova V, Vask\u00f9 V. Pyoderma gangraenosum associated with autoimmune thyreopathy and hyperandrogenic syndrome. Acta Dermatovenerol Alp Panonica Adriat. 2005;14:57\u201360.","journal-title":"Acta Dermatovenerol Alp Panonica Adriat"},{"key":"285_CR54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2230.2006.02184.x","volume":"31","author":"C Livideanu","year":"2006","unstructured":"Livideanu C, Lipsker D, Paul C, Juillard J, Schubert B. Pyoderma gangrenosum as initial manifestation of Graves\u2019 disease. Clin Exp Dermatol. 2006;31:659\u201361.","journal-title":"Clin Exp Dermatol"},{"key":"285_CR55","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/archderm.1992.01680180054005","volume":"128","author":"WL Matis","year":"1992","unstructured":"Matis WL, Ellis CN, Griffiths CEM, Lazarus GS. Treatment of pyoderma gangrenosum with cyclosporin. Arch Dermatol. 1992;128:1060\u20134.","journal-title":"Arch Dermatol"},{"key":"285_CR56","doi-asserted-by":"crossref","unstructured":"O\u2019Donnell B, Powell FC. Cyclosporin treatment of pyoderma gangrenosum. J Am Acad Dermatol. 1991;24:141\u20133.","DOI":"10.1016\/S0190-9622(08)80051-5"},{"key":"285_CR57","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s001050050324","volume":"46","author":"M Zumdick","year":"1995","unstructured":"Zumdick M, Goerz G, Schuppe HC, Milde P, Ruzicka T. Niedrig dosierte Cyclosporin-A-Therapie bei Pyoderma gangraenosum. Erfahrungen bei 6 Patienten. Hautarzt. 1995;46:697\u2013701.","journal-title":"Hautarzt"},{"key":"285_CR58","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1046\/j.1365-2133.1997.20022083.x","volume":"137","author":"P Driesch Van den","year":"1997","unstructured":"Van den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol. 1997;137:1000\u20135.","journal-title":"Br J Dermatol"},{"key":"285_CR59","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/archderm.1989.01670130059007","volume":"125","author":"JH Prystowsky","year":"1989","unstructured":"Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Arch Dermatol. 1989;125:57\u201364.","journal-title":"Arch Dermatol"},{"key":"285_CR60","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","volume":"32","author":"JL Arbiser","year":"1995","unstructured":"Arbiser JL, Moschella SL. Clofazimine: a review of its medical uses and mechanisms of action. J Am Acad Dermatol. 1995;32:241\u20137.","journal-title":"J Am Acad Dermatol"},{"key":"285_CR61","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2165\/00003495-200060020-00003","volume":"60","author":"V Peuckmann","year":"2000","unstructured":"Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs. 2000;60:273\u201392.","journal-title":"Drugs"},{"key":"285_CR62","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1046\/j.1468-3083.2000.00019.x","volume":"14","author":"U Wollina","year":"2000","unstructured":"Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol. 2000;14:187\u201390.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"285_CR63","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1001\/archderm.140.12.1427","volume":"140","author":"NH Daniels","year":"2004","unstructured":"Daniels NH, Callen JP. Mycophenolate mofetil is an effective treatment for peristomal pyoderma gangrenosum. Arch Dermatol. 2004;140:1427\u20139.","journal-title":"Arch Dermatol"},{"key":"285_CR64","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/09546630410020154","volume":"15","author":"MR Lee","year":"2004","unstructured":"Lee MR, Cooper AJ. Mycophenolate mofetil in pyoderma ganrenosum. J Dermatolog Treat. 2004;15:303\u20137.","journal-title":"J Dermatolog Treat"},{"key":"285_CR65","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00054725-200407000-00014","volume":"10","author":"DC Baumgart","year":"2004","unstructured":"Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421\u20134.","journal-title":"Inflamm Bowel Dis"},{"key":"285_CR66","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000079897","volume":"209","author":"GJ Kontochristopoulos","year":"2004","unstructured":"Kontochristopoulos GJ, Stavropoulos PG, Gregoriou S, Zakopoulou N. Treatment of pyoderma gangrenosum with low-dose colchicine. Dermatology. 2004;209:233\u20136.","journal-title":"Dermatology"},{"key":"285_CR67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2036.2006.02988.x","volume":"24","author":"C Schmidt","year":"2006","unstructured":"Schmidt C, Wittig BM, Moser C, Zeitz M, Stallmach A. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn\u2019s disease. Aliment Pharmacol Ther. 2006;24:343\u201350.","journal-title":"Aliment Pharmacol Ther"},{"key":"285_CR68","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.5.6.1333","volume":"5","author":"K Budde","year":"2004","unstructured":"Budde K, Glander P, Diekmann F, Waiser J, Fritsche L, Dragun D, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother. 2004;5:1333\u201345.","journal-title":"Expert Opin Pharmacother"},{"key":"285_CR69","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/j.1365-2133.2004.06249.x","volume":"151","author":"E Fujimoto","year":"2004","unstructured":"Fujimoto E, Fujimoto N, Kuroda K, Tajima S. Leukocytapheresis treatment for pyoderma gangrenosum. Br J Dermatol. 2004;151:1090\u20132.","journal-title":"Br J Dermatol"},{"key":"285_CR70","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-4632.2004.01986.x","volume":"43","author":"S Mori","year":"2004","unstructured":"Mori S, Nagashima M, Yoshida K, Yoshino K, Aoki M, Kawana S, et al. Granulocyte adsorptive apheresis for leg ulcers complicated by rheumatoid arthritis: a report on three successfully treated cases. Int J Dermatol. 2004;43:732\u20135.","journal-title":"Int J Dermatol"},{"key":"285_CR71","first-page":"1590","volume":"3","author":"G Girolomoni","year":"2002","unstructured":"Girolomoni G, Pastore S, Albanesi C, Cavani A. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs. 2002;3:1590\u20135.","journal-title":"Curr Opin Investig Drugs"},{"key":"285_CR72","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2133.2003.05294.x","volume":"148","author":"D Mimouni","year":"2003","unstructured":"Mimouni D, Anhalt GJ, Kouba DJ, Nousari HC. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol. 2003;148:813\u20136.","journal-title":"Br J Dermatol"},{"key":"285_CR73","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1023\/B:DDAS.0000042245.20042.4f","volume":"49","author":"MS Sapienza","year":"2004","unstructured":"Sapienza MS, Cohen S, Dimarino AJ. Treatment of pyoderma gangrenosum with infliximab in Crohn\u2019s disease. Dig Dis Sci. 2004;49:1454\u20137.","journal-title":"Dig Dis Sci"},{"key":"285_CR74","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s00296-004-0467-8","volume":"25","author":"I Kaufman","year":"2005","unstructured":"Kaufman I, Caspi D, Yeshurun D, Dotan I, Yaron M, Elkayam O. The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease. Rheumatol Int. 2005;25:406\u201310.","journal-title":"Rheumatol Int"},{"issue":"Suppl 2","key":"285_CR75","first-page":"128","volume":"54","author":"DB Roy","year":"2006","unstructured":"Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006;54(Suppl 2):128\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"285_CR76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s13555-012-0006-6","volume":"2","author":"L Hinterberger","year":"2012","unstructured":"Hinterberger L, M\u00fcller CS, Vogt T, Pf\u00f6hler C. Adalimumab: a treatment option for pyoderma gangrenosum after failure of systemic standard therapies. Dermatol Ther (Heidelb). 2012;2(1):6.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"285_CR77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nri2691","volume":"10","author":"JE Sims","year":"2010","unstructured":"Sims JE, Smith DE. The IL-1 family: regulators of immunity. Nat Rev Immunol. 2010;10:89\u2013102.","journal-title":"Nat Rev Immunol"},{"key":"285_CR78","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1007\/s11926-013-0392-5","volume":"16","author":"S Steiger","year":"2014","unstructured":"Steiger S, Harper JL. Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep. 2014;16:392.","journal-title":"Curr Rheumatol Rep"},{"key":"285_CR79","doi-asserted-by":"crossref","first-page":"e2595","DOI":"10.1371\/journal.pntd.0002595","volume":"7","author":"AH Tavares","year":"2013","unstructured":"Tavares AH, Magalh\u00e3es KG, Almeida RD, Correa R, Burgel PH, Bocca AL. NLRP3 Inflammasome activation by Paracoccidioides brasiliensis. PLoS Negl Trop Dis. 2013;7:e2595.","journal-title":"PLoS Negl Trop Dis"},{"key":"285_CR80","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","volume":"39","author":"C Garlanda","year":"2013","unstructured":"Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Immunity. 2013;39:1003\u201318.","journal-title":"Immunity"},{"key":"285_CR81","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fcimb.2013.00076","volume":"3","author":"LD Cunha","year":"2013","unstructured":"Cunha LD, Zamboni DS. Subversion of inflammasome activation and pyroptosis by pathogenic bacteria. Front Cell Infect Microbiol. 2013;3:76.","journal-title":"Front Cell Infect Microbiol"},{"key":"285_CR82","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/IAI.01097-13","volume":"82","author":"L Mao","year":"2014","unstructured":"Mao L, Zhang L, Li H, Chen W, Wang H, Wu S, et al. Pathogenic fungus Microsporum canis activates the NLRP3 inflammasome. Infect Immun. 2014;82:882\u201392.","journal-title":"Infect Immun"},{"key":"285_CR83","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1038\/ni.1960","volume":"11","author":"EA Miao","year":"2010","unstructured":"Miao EA, Leaf IA, Treuting PM, Mao DP, Dors M, Sarkar A, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11:1136\u201342.","journal-title":"Nat Immunol"},{"key":"285_CR84","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1365-2133.2009.09404.x","volume":"161","author":"M Brenner","year":"2009","unstructured":"Brenner M, Ruzicka T, Plewig G, Thomas P, Herzer P. Targeted treatment of pyoderma gangrenosum in PAPA (pyogenic arthritis, pyoderma gangrenosum and acne) syndrome with the recombinant human interleukin-1 receptor antagonist anakinra. Br J Dermatol. 2009;161:1199\u2013201.","journal-title":"Br J Dermatol"},{"key":"285_CR85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","volume":"66","author":"M Braun-Falco","year":"2012","unstructured":"Braun-Falco M, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2013a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol. 2012;66:409\u201315.","journal-title":"J Am Acad Dermatol"},{"key":"285_CR86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/00054725-200407000-00014","volume":"10","author":"DC Baumgart","year":"2004","unstructured":"Baumgart DC, Wiedenmann B, Dignass AU. Successful therapy of refractory pyoderma gangrenosum and periorbital phlegmona with tacrolimus [FK506] in ulcerative colitis. Inflamm Bowel Dis. 2004;10:421\u20134.","journal-title":"Inflamm Bowel Dis"},{"key":"285_CR87","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1463-1318.2004.00607.x","volume":"6","author":"M Khurrum Baig","year":"2004","unstructured":"Khurrum Baig M, Marquez H, Nogueras JJ, Weiss EG, Wexner SD. Topical tracrolimus [FK506] in the treatment of recalcitrant parastomal pyoderma gangrenosum associated with Crohn\u2019s disease: report of two cases. Colorectal Dis. 2004;6:250\u20133.","journal-title":"Colorectal Dis"},{"key":"285_CR88","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/1752-1947-7-106","volume":"7","author":"U Wollina","year":"2013","unstructured":"Wollina U. Letter to the editor: Temporary renal insufficiency associated with topical tacrolimus treatment of multilocal pyoderma gangrenosum. J Dermatol Case Rep. 2013;7:106\u20137.","journal-title":"J Dermatol Case Rep"},{"key":"285_CR89","first-page":"44","volume":"58","author":"K Neiderer","year":"2012","unstructured":"Neiderer K, Martin B, Hoffman S, Jolley D, Dancho J. A mechanically powered negative pressure device used in conjunction with a bioengineered cell-based product for the treatment of pyoderma gangrenosum: a case report. Ostomy Wound Manage. 2012;58:44\u20138.","journal-title":"Ostomy Wound Manage"},{"key":"285_CR90","doi-asserted-by":"crossref","unstructured":"Hill DS, O\u2019Neill JK, Toms A, Watts AM. Pyoderma gangrenosum: a report of a rare complication after knee arthroplasty requiring muscle flap cover supplemented by negative pressure therapy and hyperbaric oxygen. J Plast Reconstr Aesthet Surg. 2011;64:1528\u201332.","DOI":"10.1016\/j.bjps.2011.03.024"},{"key":"285_CR91","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1001\/archderm.143.10.1249","volume":"143","author":"MM Ghersi","year":"2007","unstructured":"Ghersi MM, Ricotti C, Nousari CH, Newman MI. Negative pressure dressing in the management of pyoderma gangrenosum ulcer. Arch Dermatol. 2007;143:1249\u201351.","journal-title":"Arch Dermatol"},{"key":"285_CR92","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/1752-1947-6-98","volume":"6","author":"JM Mir-Bonaf\u00e9","year":"2012","unstructured":"Mir-Bonaf\u00e9 JM, Blanco-Barrios S, Romo-Melgar A, Santos-Briz A, Fern\u00e1ndez-L\u00f3pez E. Photoletter to the editor: Localized pyoderma gangrenosum after interferon-alpha2b injections. J Dermatol Case Rep. 2012;6:98\u20139.","journal-title":"J Dermatol Case Rep"},{"key":"285_CR93","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1365-2133.2008.08599.x","volume":"159","author":"K ten Freyhaus","year":"2008","unstructured":"ten Freyhaus K, Homey B, Bieber T, Wilsmann-Theis D. Pyoderma gangrenosum: another cutaneous side-effect of sunitinib? Br J Dermatol. 2008;159:242\u20133.","journal-title":"Br J Dermatol"},{"key":"285_CR94","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1200\/JCO.2010.32.6165","volume":"29","author":"LD Nadauld","year":"2011","unstructured":"Nadauld LD, Miller MB, Srinivas S. Pyoderma gangrenosum with the use of sunitinib. J Clin Oncol. 2011;29:e266\u20137.","journal-title":"J Clin Oncol"},{"key":"285_CR95","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1111\/j.1365-4632.2006.02749.x","volume":"45","author":"R Sagara","year":"2006","unstructured":"Sagara R, Kitami A, Nakada T, Iijima M. Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions. Int J Dermatol. 2006;45:1002\u20133.","journal-title":"Int J Dermatol"},{"key":"285_CR96","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/15569520903178208","volume":"28","author":"I Bustillo","year":"2009","unstructured":"Bustillo I, Kaley K, Saif MW. Rash associated with the use of pegylated filgrastim in a patient with advanced pancreatic cancer. Cutan Ocul Toxicol. 2009;28:181\u20134.","journal-title":"Cutan Ocul Toxicol"},{"key":"285_CR97","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/j.1365-4632.2008.03662.x","volume":"47","author":"MP Tinoco","year":"2008","unstructured":"Tinoco MP, Tamler C, Maciel G, Soares D, Avelleira JC, Azulay D. Pyoderma gangrenosum following isotretinoin therapy for acne nodulocystic. Int J Dermatol. 2008;47:953\u20136.","journal-title":"Int J Dermatol"},{"key":"285_CR98","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jaad.2005.09.017","volume":"55","author":"A Freiman","year":"2006","unstructured":"Freiman A, Brassard A. Pyoderma gangrenosum associated with isotretinoin therapy. J Am Acad Dermatol. 2006;55:107\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"285_CR99","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000077844","volume":"208","author":"SB Hong","year":"2004","unstructured":"Hong SB, Lee MH. A case of propylthiouracil-induced pyoderma gangrenosum associated with antineutrophil cytoplasmic antibody. Dermatology. 2004;208:339\u201341.","journal-title":"Dermatology"},{"key":"285_CR100","first-page":"253","volume":"67","author":"A Srebrnik","year":"2001","unstructured":"Srebrnik A, Shachar E, Brenner S. Suspected induction of a pyoderma gangrenosum-like eruption due to sulpiride treatment. Cutis. 2001;67:253\u20136.","journal-title":"Cutis"}],"container-title":["Wiener Medizinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-014-0285-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10354-014-0285-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10354-014-0285-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T11:28:11Z","timestamp":1597922891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10354-014-0285-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,5]]},"references-count":100,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["285"],"URL":"https:\/\/doi.org\/10.1007\/s10354-014-0285-x","relation":{},"ISSN":["0043-5341","1563-258X"],"issn-type":[{"value":"0043-5341","type":"print"},{"value":"1563-258X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,5]]}}}